Fimea produces and compiles assessments of the therapeutic and economic value of medicines and coordinates the related collaboration. The operations focus on the assessment of new hospital-only medicinal products. Additionally, Fimea may produce other kind of assessments and reviews that vary in terms of scope and content, depending on the topic and purpose of the assessment. The medicines to be assessed must have a marketing authorisation granted by Fimea or the European Commission.
In the assessment of pharmacotherapies, Fimea engages in collaboration with the Council for Choices in Health Care in Finland (COHERE Finland), the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA), hospital districts, clinical experts and other national stakeholders. Fimea also engages in international assessment cooperation in the Nordic FINOSE network and in the European EUnetHTA network.